Project Name: Collaborative Working York Hospital Breast Cancer Service Redesign

Project Summary:

This Collaborative Working Project (“CWP”) aims to optimise workforce capacity within the York and Scarborough Teaching Hospitals NHS Trust breast cancer (“BC”) oncology service with the creation of new dedicated workforce roles to include one breast cancer care coordinator and one breast cancer nurse specialist band 7  for a period of 12 months. 

The intention is to maximise efficiency of clinical appointments that will improve the pathway for patients providing a more efficient and coordinated approach to care.  

The new roles will support the breast oncology multidisciplinary team and coordinate the pathway for patients with primary and secondary breast cancer.

Planned Milestones:

  1. CW Partner and Novartis: Kick-off meeting.

2. CW Partner: Collection of baseline data, in line with the Project Outcome Measures & Data Collection table including patient experience. Setting up the clinic codes and physical clinic space.

3. CW Partner: Confirmation of recruitment of band 7 nurse and CCC.

4. CW Partner: Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity (CW Partner shall ensure that the clinical staff covered by the Novartis Financial Contribution are in place, trained and ready to begin clinical activity). 

CW Partner: Collection & submission of 3 months clinical activity data.

5. CW Partner: Collection & submission of 6 months clinical activity data.

6. CW Partner: Development of business case.

7. CW Partner: Submission of business case by the CW Partner team to relevant body within the NHS Board.

8. CW Partner: Collection & submission of 9 months clinical activity data.

9. CW Partner: Collection & submission of 12 months clinical activity data. 

10. CW Partner: Submit final CWP report to Novartis within 2 months completion of the clinical work. 

Expected Benefits:

ANTICIPATED BENEFITS FOR PATIENTS

  • Increased access to equitable, consistent, and standardised care.
  • Increased access to education on BC and treatments to improve adherence and consequently improve patients' outcomes, supported by a personalised care plan.  
  • Reduce patient waits in the clinic given extra capacity created by new workforce role. 
  • Reduce unplanned medical reviews and admissions.

 

ANTICIPATED BENEFITS FOR THE ORGANISATION(S) 

  • Increase the overall quality of care and improve equity of access to specialist care for patients with BC requiring treatment initiation, evaluation, and monitoring. 
  • Provision of subject matter expertise to educate other members of the clinical team on treatment options. 
  • Provide a single point of contact for patients, thereby reducing the potential for unplanned calls being received by the wider clinical team. 
  • Free up consultant capacity for clinical activities that are unique to their skillset. 
  • Reduce use of emergency triage line and unplanned admissions.

 

ANTICIPATED BENEFITS FOR NOVARTIS 

  • Better understanding of overall customers’ and patients’ needs; 
  • Optimal use of medicines (including Novartis medicines) in appropriate patients. 
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisations.

 

Start Date & Duration: December 2024 for 18 months

FA-11306859